

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**






## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 38/19, G01N 33/68, C07K 14/52</b>		A1	(11) International Publication Number: <b>WO 95/28172</b>
			(43) International Publication Date: <b>26 October 1995 (26.10.95)</b>
(21) International Application Number: <b>PCT/CA95/00205</b>		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: <b>11 April 1995 (11.04.95)</b>			
(30) Priority Data: <b>08/229,009 18 April 1994 (18.04.94) US</b>			
(60) Parent Application or Grant (63) Related by Continuation <b>US 08/229,009 (CIP) Filed on 18 April 1994 (18.04.94)</b>		Published With international search report.	
(71) Applicant (for all designated States except US): <b>OSTEOPHARM LIMITED [CA/CA]; 100 International Boulevard, Etobicoke, Ontario M9W 6J6 (CA).</b>			
(72) Inventor; and (75) Inventor/Applicant (for US only): <b>TAM, Cherk, Shing [CA/CA]; 1072 Rectory Lane, Oakville, Ontario L6M 2B7 (CA).</b>			
(74) Agents: <b>HUNT, John, C. et al.; Blake, Cassels &amp; Graydon, P.O. Box 25, Commerce Court West, Toronto, Ontario M5L 1A9 (CA).</b>			

(54) Title: **HUMAN BONE STIMULATING FACTOR**

## (57) Abstract

Polypeptides from human blood serum have been found to increase bone growth in rats. Useful to promote bone growth in mammals, and/or the treatment of osteoporosis. One polypeptide has the seventy amino acid sequence of NAP-2: Ala Glu Leu Arg Cys Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln Ser Leu Glu Val Ile Gly Lys Gly Thr His Cys Asn Gln Val Glu Val Ile Ala Thr Leu Lys Asp Gly Arg Lys Ile Cys Leu Asp Pro Asp Ala Pro Arg Ile Lys Lys Ile Val Gln Lys Lys Leu Ala Gly Asp Glu Ser Ala Asp. The other polypeptide has the seventy-five amino acid sequence of a previously sequenced variant of NAP-2: Asp Ser Asp Leu Tyr Ala Glu Leu Arg Cys Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln Ser Leu Glu Val Ile Gly Lys Gly Thr His Cys Asn Gln Val Glu Val Ile Ala Thr Leu Lys Asp Gly Arg Lys Ile Cys Leu Asp Pro Asp Ala Pro Arg Ile Lys Lys Ile Val Gln Lys Lys Leu Ala Gly Asp Glu Ser Ala Asp. Both polypeptides have been found to increase bone growth in rats.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## HUMAN BONE STIMULATING FACTOR

It is known that even in the adult human, bone is subject to turnover. In certain locations, such as the internal auditory capsule, there is apparently no turnover after the organ is formed. In other locations, particularly in the central skeletal axis, the turnover appears to continue during adulthood. Bone turnover occurs on the surface of the existing bone matrix, which is composed of protein (mainly collagen) and minerals. Bone turnover is initiated with the destruction of bone matrix by osteoclasts. The osteoclast is a multinucleated cell which secretes acid and proteolytic enzymes leading to the lysis of the collagen matrix protein and the release of minerals into the extracellular fluid compartment. Following this initial phase of bone destruction, or resorptive phase, formation of new bone protein matrix sets in. New bone proteins are deposited, and sometime later, minerals begin to be incorporated into the newly formed matrix. The formation of bone matrix and its subsequent mineralization are functions of osteoblasts, which are mononucleated cells. The formation phase is often followed by a period of inactivity (1,2). *In vivo*, resorption appears to be tightly coupled with formation (3) and bone turnover is thus a succession of events; the location of which is known as the Bone Metabolism Unit or the BMU. Osteoblasts and osteoclasts, the putative mediators of bone turnover are thought to belong to two distinct cell lineages. These two cell types are not preformed cells, but they differentiate from their precursors through cell activation (4,5,6).

Bone matrix can either be maintained by a cessation of bone turnover as for the bone of the internal auditory capsule, or by a balance between resorption and formation. In many studies on skeletal changes in relation to age, a gain in the total body bone volume is observed during the growth period and the skeletal mass reaches a maximum during early adulthood. This gain is followed by a fall in bone volume with age. In females, a phase of more rapid bone loss often occurs during the perimenopausal period before a slower steadier phase. For this reason, bone loss in the female tends to be more severe than in the male. An understanding of bone balance in the BMU may thus be critical to understanding the pathogenesis of skeletal aging. In any case, mechanisms controlling bone turnover are complex and are not well understood at this time. The complexity of the control mechanisms has resulted in a variety of approaches to reducing bone loss.

Bone turnover can be regulated at two different stages. It can be regulated at the stage of the activation of precursor cells. Regulators of cellular activation can control not only the number of active BMU in the skeleton, but possibly also the number of osteoclasts and osteoblasts in an individual BMU. Bone turnover secondly can be regulated at the level of differentiated bone cells. The complexity of the bone cell system makes the separate study of these two levels of regulation difficult (3).

Regulators of bone cells appear to fall into two categories. The first type interacts with specific receptors on cell membranes. One class of these regulators acts through the adenylate cyclase system with the generation of intra-cellular cyclic AMP as the second messenger acting on the protein kinase K system. Parathyroid hormone (PTH) and calcitonin (CT) belong to this class (7). A second class also interacts with a membrane receptor and results in the intracellular release of a molecule derived from phosphoinositides which in turn leads to an increase in intracellular calcium and

activation of Kinase C. A third class involves interaction of the regulator with a cell surface receptor but the second signal is generated by the receptor molecule itself with the subsequent activation of tyrosine Kinase. Many of the growth factors appear to act in this way (8-15). Regulators falling into the second category do not interact with a cell membrane receptor, but can cross the cell membrane to bind with a cytosolic receptor. The regulator is then transported across the nuclear membrane by the cytosolic receptor to interact with the DNA resulting in increased transcription of specific genes. Steroid hormones, including vitamin D, appear to act in this manner (16).

Many hormones stimulate the proliferation of osteoclasts. These include  $1,25(\text{OH})_2\text{D}$ , PTH and prostaglandins. PTH and  $1,25(\text{OH})_2\text{D}$  receptors in osteoclasts have apparently not yet been identified. These two hormones seem to have no effect on osteoclasts in culture. However, when osteoclasts are co-cultured with osteoblast-like cell lines, PTH and  $1,25(\text{OH})_2\text{D}$  stimulate the proliferation of osteoclasts. IL-1 and TNF appear to act in a similar way as PTH and  $1,25(\text{OH})_2\text{D}$ . Other growth factors, like EGF, TGF and PDGF appear to stimulate osteoclasts through increased production of PGE. Calcitonin and corticosteroids are known osteoclast inhibitors along with chemicals such as diphosphonates.

It is currently believed that interleukin 1 may stimulate collagen and non-collagen bone protein and DNA synthesis. The effect on bone protein synthesis is blocked by indomethacin, suggesting that this action of IL-1 is mediated through PGE. Indomethacin seems to have no effect on the IL-1 effect on osteoblast DNA synthesis. In culture studies on osteoblast-like cell lines suggest that some locally produced growth factors stimulate DNA and collagen synthesis. In bone cell culture, PTH or Vitamin D suppresses collagen synthesis. This *in vitro* effect of PTH contrasts with the *in vivo* effect observed in human subjects and experimental animals. It has been demonstrated in rats and in human hyperparathyroid patients that PTH can stimulate the deposition of mineralized bone matrix. Preliminary clinical trial studies on the efficacy of the PTH 1-34 amino acid fragment in the treatment of osteoporosis indicate that this PTH fragment can increase the trabecular volume. The reason for this discrepancy is not yet fully explained.

Parathyroid hormone is a peptide of 84 amino acids in its mature form. Initially translated pre-pro-parathyroid hormone is much larger, the pre sequence being a signal sequence which is cleaved when the peptide enters the rough endoplasmic reticulum. In the golgi apparatus, the pro-sequence is cleaved off leaving the intact mature hormone packaged in the secretory granule. It appears that regulation of the rate of secretion is governed not so much by the rate of production of the intracellular peptide, but in the rate of intracellular destruction and in the rate of secretion. Intracellularly, the mature peptide is truncated at both the amino and the carboxyl termini. The truncated peptide may be secreted into circulation as an inactive fragment. The secretion of the mature peptide can be stimulated by a drop in the extracellular calcium concentration. An elevated serum calcium concentration on the other hand appears to suppress the secretion of PTH. Once in circulation, the mature peptide is rapidly cleaved in the liver at many sites of the molecule including the region of the 38 amino acid residue. The smaller fragment at the amino terminal end, which includes the first 34 amino acids, carries the full known biological activity in terms of its action on the kidney, the intestine.

and the bone. It also binds fully to the cell membrane receptor to stimulate cAMP production. The level of the 1-38 fragment in the serum is normally unmeasurable indicating that it has a short circulatory life. The larger inactive carboxyl terminal fragment has a relatively long half life and carries the highest proportion of the immunoreactive PTH in the circulatory system. All fragments in circulation are eventually destroyed in the kidney and the liver. One of the renal mechanisms for elimination of the circulating inactive PTH fragments is glomerular filtration (17).

PTH participates in calcium and skeletal homeostasis. PTH stimulates the tubular resorption of calcium by the kidney and inhibits the reabsorption of phosphate and bicarbonate by the proximal renal tubules. A second effect of PTH on the kidney is the stimulation of  $1,25(\text{OH})_2\text{D}$  production. This vitamin D metabolite is an *in vivo* stimulator of osteoclasts as well as an enhancer of intestinal calcium absorption. The increase in calcium absorption by the intestine following PTH stimulation is mediated by this vitamin D metabolite. *In vivo*, PTH stimulates osteoclastic bone resorption with the release of calcium into the circulation. PTH also causes proliferation of osteoblasts (18). In many cases of hyperparathyroidism there is a skeletal loss. However, an increase in spinal density has been reported in some cases of primary hyperparathyroidism (19,20,21) as well as in secondary hyperparathyroidism complicating renal failure. Kalu and Walker have observed that chronic administration of low doses of parathyroid extract led to sclerosis of bone in the rat (22). Tam et al. studied the effect of low calcium diet on the bone mineral apposition rate in the rat by tetracycline labelling and found that despite the loss of bone due to increase in bone resorption histologically (as a result of secondary hyperparathyroidism), the bone mineral apposition rate was increased (23). It was also found that the bone mineral apposition rate was increased in 23 human patients with mild primary hyperparathyroidism (24). After successful removal of parathyroid adenoma from four of the patients, the rate returned to the level observed in control subjects. There has also been found to be a dose dependent stimulation of the mineral apposition rate by PTH. The potency of the 1-34 fragment and the intact PTH hormone appears to be about the same on a molar basis. This is consistent with the 1-34 fragment of the PTH molecule carrying the biological activity of the intact hormone. It has also been observed that the end result of the administration of PTH on skeletal homeostasis depends on how the hormone is administered. For the same daily dose, the bone volume shows a dose dependent increase if the daily dose of the hormone is given as one single injection. However, when the same daily dose is administered by continuous infusion with a subcutaneous miniosmotic pump, the result is bone loss. Intermittent injection causes practically no effect on the serum calcium levels whereas infusion causes a dose dependent increase in the serum calcium. The effects of PTH administered by these two routes on bone mineral apposition rate as measured by tetracycline labelling are the same. What accounts for this differential effect is not understood (25).

Given the general understanding of bone growth and its regulation, various approaches to treatment of diseases involving reduction of bone mass and accompanying disorders are exemplified in the patent literature. For example, PCT Patent Application No. 9215615 published September 17, 1992 describes a protein derived from a porcine pancreas which acts to depress serum calcium levels for treatment of bone disorders that cause elevation of serum calcium levels. European

Patent Application No. 504938 published September 23, 1992 describes the use of di- or tripeptide which inhibit cysteine protease in the treatment of bone diseases. PCT Patent Application No. 9214, published September 3, 1992 discloses a composition for inducing bone growth, the composition containing activin and bone morphogenic protein. European Patent Application No. 499242 published August 19, 1992 describes the use of cell growth factor compositions thought to be useful in bone diseases involving bone mass reduction because they cause osteoblast proliferation. PCT Patent Application No. 4039656 published June 17, 1992 describes a drug containing the human N-terminal PTH fragment 1 - 37. European Patent Application No. 451867 published September 16, 1991 describes parathyroid hormone peptide antagonists for treating dysbolism associated with calcium or phosphoric acid, such as osteoporosis.

The relatively short half life of PTH in the blood serum and the relatively lengthy effect of intermittent PTH injection led the present investigator to the hypothesis that PTH may in some way lead to induction of a second factor into the circulatory system. The presence of such a second factor in blood serum of rats and of humans has thus been investigated.

As disclosed in prior international patent application published under WO 94/20615 on 15 September 1994, it has been found possible to isolate from rat blood serum a polypeptide substance which, upon administration to rats incapable of producing PTH (parathyroidectomized rats), produces an increase in the observed bone mineral apposition rate as determined using tetracycline labelling. As also disclosed in the published application, a nucleic acid probe based on the amino acid sequence of the rat polypeptide has been synthesized and used to screen a human liver cDNA fetal library in order to isolate a human nucleic acid sequence coding for a human bone apposition polypeptide. A chemically synthesized polypeptide corresponding to a portion of the isolated sequence was found to increase the bone apposition rate in rats in a dose dependent fashion as determined using tetracycline labelling.

It has also been possible to isolate a polypeptide from human blood serum capable of causing an increased bone mineral apposition rate in parathyroidectomized rats. The first eighteen amino acids of the N-terminus of the human isolate, termed here "human bone stimulating factor" have now been determined to resemble a sequence contained in certain previously isolated polypeptides: human  $\beta$ -thromboglobulin (BTG), connective tissue-activating peptide III (CTAP-III) and a variant of neutrophil-activating peptide (NAP-2).

The sequence of BTG was published by Poncz *et al.* in 1991 (26): Gly Lys Glu Glu Ser Leu Asp Ser Asp Leu Tyr Ala Glu Leu Arg Cys Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln Ser Leu Glu Val Ile Gly Lys Gly Thr His Cys Asn Gln Val Glu Val Ile Ala Thr Leu Lys Asp Gly Arg Lys Ile Cys Leu Asp Pro Asp Ala Pro Arg Ile Lys Lys Ile Val Gln Lys Lys Leu Ala Gly Asp Glu Ser Ala Asp (SEQ ID NO:1).

Walz *et al.* has published polypeptide sequences identified as neutrophil-activating peptide (NAP-2)(27): Ala Glu Leu Arg Cys Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln Ser Leu Glu Val Ile Gly Lys Gly Thr His Cys Asn Gln Val Glu Val Ile Ala Thr Leu Lys Asp Gly Arg Lys Ile Cys Leu Asp Pro Asp Ala Pro Arg Ile Lys Lys Ile Val Gln Lys Lys Leu Ala Gly Asp C



Ser Ala Asp (SEQ ID NO:2); and CTAP-III, (27): Asn Leu Ala Lys Gly Lys Glu Glu Ser Leu Asp  
 Ser Asp Leu Tyr Ala Glu Leu Arg Cys Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln  
 Ser Leu Glu Val Ile Gly Lys Gly Thr His Cys Asn Gln Val Glu Val Ile Ala Thr Leu Lys Asp Gly Arg  
 Lys Ile Cys Leu Asp Pro Asp Ala Pro Arg Ile Lys Lys Ile Val Gln Lys Lys Leu Ala Gly Asp Glu Ser  
 5 Ala Asp (SEQ ID NO:3). These sequences have also been described in PCT Patent Application No.  
 9006321 published June 14, 1990.

Walz *et al.* also identified a variant of NAP-2 as a cleavage product of the platelet  
 $\alpha$ -granule component platelet basic protein (PBP), which is termed here NAP-2V (27): Asp Ser Asp  
 Leu Tyr Ala Glu Leu Arg Cys Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln Ser Leu  
 10 Glu Val Ile Gly Lys Gly Thr His Cys Asn Gln Val Glu Val Ile Ala Thr Leu Lys Asp Gly Arg Lys Ile  
 Cys Leu Asp Pro Asp Ala Pro Arg Ile Lys Lys Ile Val Gln Lys Lys Leu Ala Gly Asp Glu Ser Ala Asp  
 (SEQ ID NO:4). NAP-2V is related to NAP-2 in that NAP-2V has an additional five amino acid  
 residues located at its N-terminus and the N-terminus of NAP-2V resembles the N-terminus of the first  
 twenty amino acids of the human bone stimulating factor.

15 Walz *et al.* also found that NAP-2V had considerably less neutrophil-stimulating  
 activity than NAP-2 and have postulated that NAP-2 is indicated for use in the treatment of conditions  
 in which an increase of the number or enhancement of the activation state of the PMN  
 (polymorphonuclear cells - neutrophils) leads to clinical improvement, e.g. in bacterial, mycoplasma,  
 yeast and fungal, and in viral infections. NAP-2 was thus suggested as an indication for use in  
 20 inflammatory illnesses such as psoriasis, arthritic conditions and asthma. The precise function of either  
 NAP-2 or NAP-2V remains unknown, however.

In any case, chemically synthesized polypeptides having the sequences of each of  
 NAP-2 (SEQ ID NO:2) and NAP-2V (SEQ ID NO:4) have now been found to increase bone growth in  
 rats.

25 The present invention thus provides, in a particular aspect, a method of increasing  
 bone growth in a mammal by administering a therapeutically effective amount of a polypeptide having  
 the amino acid sequence Asp-Ser-Asp-Leu-Tyr-Ala-Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-  
 Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-Ser-Leu-Glu-Val-Ile-Gly-Lys-Gly-Thr-His-Cys-Asn-Gln-Val-Glu-Val-  
 Ile-Ala-Thr-Leu-Lys-Asp-Gly-Arg-Lys-Ile-Cys-Leu-Asp-Pro-Asp-Ala-Pro-Arg-Ile-Lys-Lys-Ile-Val-Gln-  
 30 Lys-Lys-Leu-Ala-Gly-Asp-Glu-Ser-Ala-Asp or the amino acid sequence Ala-Glu-Leu-Arg-Cys-Met-  
 Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-Ser-Leu-Glu-Val-Ile-Gly-Lys-Gly-Thr-His-  
 Cys-Asn-Gln-Val-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asp-Gly-Arg-Lys-Ile-Cys-Leu-Asp-Pro-Asp-Ala-Pro-  
 Arg-Ile-Lys-Lys-Ile-Val-Gln-Lys-Lys-Leu-Ala-Gly-Asp-Glu-Ser-Ala-Asp, a portion of one of the  
 sequences capable of increasing bone growth, or a combination thereof. The invention includes  
 35 administration of a polypeptide having an amino acid sequence sufficiently duplicative of one of the  
 mentioned sequences to be capable of increasing bone growth in the mammal, or a combination of such  
 polypeptides. The method includes administering a therapeutically effective amount of a polypeptide  
 having an amino acid sequence having at least about 50%, 60%, 70%, 80% or 90% homology with  
 SEQ ID NO: 2, SEQ ID NO:4, or a combination thereof.

In another aspect, a method according to the present invention includes increasing bone growth in a mammal by administering a therapeutically effective amount of a polypeptide having the amino acid sequence Asp-Ser-Asp-Leu-Tyr-Ala-Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-Ser-Leu-Glu-Val-Ile-Gly-Lys-Gly-Thr-His-Cys-Asn-Gln-Val-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asp-Gly-Arg-Lys-Ile-Cys-Leu-Asp-Pro-Asp-Ala-Pro-Arg-Ile-Lys-Lys-Ile-Val-Gln-Lys-Lys-Leu-Ala-Gly-Asp-Glu-Ser-Ala-Asp, analogues thereof wherein the amino acids in the sequence may be substituted, deleted or added, so long as the bone stimulatory activity in mammals derived from the three dimensional conformation of the sequence is preserved, conjugates of the polypeptide or analogues thereof; the amino acid sequence Ala-Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-Ser-Leu-Glu-Val-Ile-Gly-Lys-Gly-Thr-His-Cys-Asn-Gln-Val-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asp-Gly-Arg-Lys-Ile-Cys-Leu-Asp-Pro-Asp-Ala-Pro-Arg-Ile-Lys-Lys-Ile-Val-Gln-Lys-Lys-Leu-Ala-Gly-Asp-Glu-Ser-Ala-Asp, analogues thereof, conjugates of the polypeptide or analogues thereof; or a combination thereof.

The present invention also includes a method for determining the presence of a polypeptide that increases bone growth in a mammal in a fluid sample of a mammal, comprising linking an antibody to a polypeptide having an aforementioned sequence such as that identified as SEQ ID NO:2 or SEQ ID NO:4 and exposing the linked antibody to the sample such that the reporter system produces a detectable response when a predetermined amount of the polypeptide and the antibody are bound together.

Another aspect of the invention includes a method of detecting the presence of a protein exhibiting bone stimulatory activity in mammals, the method comprising the steps of: collecting a blood serum sample from the mammal; and exposing at least a portion of the sample to an antibody linked to a reporter system, wherein the antibody is capable of binding to a polypeptide having an aforementioned sequence, such as one of those identified as SEQ ID NO:2 or SEQ ID NO: 4, and wherein binding of the protein and antibody together causes the reporter system to indicate said binding.

The invention also includes a method of diagnosing a diseased condition such as osteoporosis in a mammal, the method comprising the steps of:

collecting a blood serum sample from the mammal;  
ascertaining whether the amount of a polypeptide having the sequence of a polypeptide of having an aforementioned sequence, such as one of those identified as SEQ ID NO:2 or SEQ ID NO:4, exceeds a predetermined level; and  
wherein a said amount of the polypeptide below the pre-determined level indicates said diseased condition.

In yet another aspect, the present invention includes a chimeric bone stimulating factor comprising a polypeptide having the amino acid sequence set forth in SEQ ID NO:2, or a portion thereof; SEQ ID NO:4, or a portion thereof; or another of the aforementioned sequences.

The invention includes the use of a polypeptide having an aforementioned sequence, such as one of those identified as SEQ ID NO:2 or SEQ ID NO:4, for the treatment of osteoporosis or to promote bone growth in a mammal.

The invention also includes a pharmaceutical composition for promoting bone growth, comprising a therapeutically effective amount of a polypeptide having an aforementioned sequence, such as one of those identified as SEQ ID NO:2 or SEQ ID NO:4.

The invention includes the use of a polypeptide having an aforementioned sequence, such as one of those identified as SEQ ID NO:2 or SEQ ID NO:4, in the preparation of a medicament for use in promoting bone growth or the treatment of osteoporosis.

## 10 DESCRIPTION OF THE DRAWINGS

In the following description, reference is made to accompanying drawings, wherein, Figures 1 to 3 are reverse phase HPLC chromatograms of human serum fraction with molecular weight between 30K and 3K. A 36.4 ml volume of human serum pooled from patients with renal failure was used. The serum was subjected to ultrafiltration to collect a fraction with MW between 30K-3K. This fraction was concentrated to about 2 ml and loaded 3 times onto a Beckman C8 column (4.6 mm x 150 mm) and run in a gradient of 10 mM Tris.Cl (pH 7.2) and 10% CH<sub>3</sub>CN. There was a peak obtained at about 20% CH<sub>3</sub>CN. Peaks from all three runs were collected and pooled. The uppermost scans were taken at 214 nm.

Figure 4 is a chromatogram showing further purification of a human serum fraction by C3 reverse phase HPLC. The pooled "x" peaks from Figures 1 to 3 were lyophilized and redissolved in 20 mM Tris.Cl (pH 7.2) and run on a Beckman C3 column (4.6 mm x 75 mm). The gradient condition was the same. A single resolved peak eluted at 30 min (about 25% CH<sub>3</sub>CN). This peak was collected.

Figure 5 shows a C8 reverse phase HPLC chromatogram of a serum fraction with MW between 30K and 3K from a normal subject. The whole serum was treated as before to collect the fraction with 30 to 3K MW. The C8 reverse phase chromatography was performed under the same conditions as stated in Figures 1 to 3. No material was retained by the column from the serum of the normal subject.

Figure 6 shows a tricine SDS electrophoretic gel of human serum protein and polypeptide fractions of material collected at pH 9.45 on a minicolumn packed with Waters QMA anion exchange packing.

Figure 7 shows a tricine SDS electrophoretic gel of human serum protein and polypeptide fractions of material collected at pH 9.45 according to an modified procedure.

Figure 8 shows the bone apposition rate ( $\mu$ m per day) for rats injected with material from bands A (N=4), B (N=4), C (N=4), D (N=3), E (N=4) and F (N=4) obtained through the modified fractionation procedure and SDS gel electrophoresis. The error bars are  $\pm$  1 S.D.

Figure 9 shows the bone apposition rate ( $\mu$ m per day) for rats injected with 25 nmol (N=5 in both cases) of chemically synthesized polypeptides having the sequences of NAP-2 (SEQ ID

NO:2) and NAP-2V (SEQ ID NO:4), respectively, compared to that of a group of control (N=5) r  
The error bars are  $\pm 1$  S.D.

## RESULTS INVOLVING NATURALLY OCCURRING HUMAN BONE STIMULATING FACTOR

### 5 INITIAL RESULTS INVOLVING A BONE STIMULATING FACTOR IN THE LOW MOLECULAR WEIGHT FRACTION OF HUMAN SERUM FROM PATIENTS WITH RENAL INSUFFICIENCY

As discussed above, human patients with renal failure may show increase in bone  
density in the radiological examination of the skeleton. These patients, because of an impaired renal  
10 synthesis of 1,25 dihydroxyvitamin D, have impaired intestinal calcium absorption and often suffer  
secondary hyperparathyroidism. Further, glomerular filtration of such patients may be reduced because  
of a reduction in the number of normal glomeruli. Many low molecular weight peptides may  
accumulate at higher than normal concentrations because of impaired glomerular filtration.

Human serum was collected from patients of the Queen Elizabeth Hospital of  
15 Toronto, Ontario, Canada suffering from mild to moderately severe renal insufficiency. Samples were  
remains of blood taken for clinical biochemical tests. Blood urea nitrogen was over 7 mM. Some  
serum samples were also from patients with severe renal insufficiency periodically attending a  
hemodialysis clinic in the Western Division of the Toronto Hospital Corporation, Toronto. A total  
36.4 ml of serum was collected.

20 Human control serum was obtained from 80 ml of blood taken 40 ml at a time from a  
normal human subject. After centrifugation 37.5 ml of serum were obtained and 36.4 ml was taken for  
fractionation. The pooled serum was centrifuged in a Beckman J2-21 centrifuge at 12,000 g for 30  
minutes at 4°C, using a JA 17 rotor. PMSF (phenylmethane sulfonyl fluoride) and DTT  
(dithiothreitol) were added to give a concentration of 1 mM each.

25 Serum components of molecular weights between 3,000 and 30,000 were fractionated  
by ultrafiltration, according to the method described in connection with rat serum in international patent  
application published under WO 94/20615. The final volume each of the test and control samples was  
2 ml and they were each lyophilized. Each lyophilized sample was dissolved in 2.1 ml of 10mM  
Tris.Cl (pH 7.2) and 100 mM NaCl. A 700  $\mu$ l volume was loaded each time for filtration through a  
30 Hewlett Packer sample filter. A C8 column was used. The program for fractionation was as follows.

Solvent A: Tris.Cl. 10 mM pH 7.2  
 Solvent B: Acetonitrile

	Time	% of A	% of B	Duration
	0'	100	0	
5	5'	50	50	50'
	55'	50	50	
	60'	100	0	5'
	75'		Stop	

The C8 column was a 4.6 x 150 mm analytical column from Beckman.

10 After the C8 reverse phase chromatography, a second reverse phase chromatography was performed on a selected peak which had been lyophilized. The sample preparation, the loading volume, and the fractionation program were the same as for C8 reverse phase. However, this time a Beckman C3 column, 4.6x 75 mm was used.

Both the test and control sera were totally run in three separate sets of loading. The  
 15 final purified peaks were lyophilized for future biological activity testing. See Figures 1 to 5.

The serum from patients with renal insufficiency showed many peaks in the C8 chromatography profile. One peak eluted shortly after 22 minutes had a high 280 nm absorption relative to 214 nm absorption, somewhat similar to the active peak identified in the rat calcium deficient serum described in international patent application published under WO 94/20615. This peak  
 20 was put through a second C3 reverse phase chromatography and a single distinct peak appeared in the second run. This final peak material was kept for biological testing.

Compared with the test serum, the elution profile of the control serum was much simpler. No sample was taken for biological testing.

## BIOLOGICAL ACTIVITY OF HUMAN ISOLATE IN RATS

### 25 MATERIALS AND METHODS

The protein concentration of the test material was determined by the Belford method as described in international patent application published under WO 94/20615. The lyophilized material was dissolved in 1.8 ml of Tris.Cl (pH 7.2) and 50 mM NaCl. An 80  $\mu$ l volume was diluted to 800  $\mu$ l with the same buffer and the protein concentration was measured in this diluted sample.

30 Twelve parathyroidectomized rats were used to test the effect of the isolate on the bone apposition rate in rats. Their pre-PTX and post PTX serum calcium concentration were 2.57 (S.D. 0.04) and 1.72 (S.D. 0.02) respectively. Six of the rats received the test material in 400  $\mu$ l and six of the rats received 400  $\mu$ l of carrier buffer as control. The bone mineral apposition rate was determined according to the same method as described in connection with material isolated from rat  
 35 serum described in international patent application published under WO 94/20615.

The concentration of the 10x diluted sample had a concentration of 3  $\mu\text{g/ml}$ . Therefore the total amount of peptide was about 52  $\mu\text{g}$ . 400  $\mu\text{l}$  of the undiluted material contained about 12  $\mu\text{g}$  of peptide. Therefore each test animal received 400  $\mu\text{l}$  of the material intravenously. The bone mineral apposition rate was 1.89  $\mu\text{m/day}$  (S.D. 0.13) and that of the control group was 0.72  $\mu\text{m/day}$  (S.D. 0.08), this difference being statistically significant ( $P < 0.025$ ).

The results indicate that, at least in patients suffering from renal failure, there is an active peptide of low molecular weight capable of stimulating the bone mineral apposition rate in parathyroidectomized rats.

Early attempts at isolating and characterizing an active human peptide were not entirely successful. Amino acid sequencing of what was thought to be a peptide, isolated through the use of gel permeation chromatography and which was shown to increase bone apposition in rats, indicated that the peptide being sequenced was most likely serum albumin.

#### PROCEDURE FOR FRACTIONATION OF HUMAN SERUM PROTEIN AND POLYPEPTIDE FRACTIONS WITH MOLECULAR WEIGHTS BETWEEN 3K AND 30K BY TRICINE SDS GEL ELECTROPHORESIS

The millitan filtration system (Millipore) and MWCO membrane of 30K, was used to filter 500 ml of human serum (from BSC) at a pressure of between 7 and 12 psi. Filtration was stopped when the filtrate volume reached  $\frac{2}{3}$  of the original serum volume. The filtrate was then collected and concentrated down to 80 ml with the same type of filtration unit and MWCO membrane of 3K.

The pH of the concentrated filtrate was adjusted to about 8.8 by the addition of ammonium hydroxide. A 5 ml volume of Waters QMA anion exchange packing was packed into a mini disposable column and equilibrated with tris buffer at pH 8.8. The concentrated filtrate was passed through the column with a vacuum negative pressure. The filtrate was collected and its pH adjusted to 9.45 with the addition of ammonium hydroxide. Another QMA cartridge was packed and equilibrated with a weak ammonium hydroxide (10 mM) solution with the pH adjusted to 9.45 by the addition of acetic acid. The filtrate eluted from the first column was passed through this minicolumn. The filtrate was discarded. The column was washed with 15 ml of water the pH of which was adjusted to 10 with ammonium hydroxide. The material retained in the column was eluted with 3 ml of 0.1% acetic acid and lyophilized.

The lyophilized material was dissolved in 200  $\mu\text{l}$  of loading buffer, and kept at 60°C for 30 minutes prior to electrophoresis.

For electrophoresis, a 1 mm thick, (Novex) 10 well 10% - 20% tricine gradient gel was used. A 20  $\mu\text{l}$  volume of the sample was loaded into each well. The sample was co-run with the same volume of MW marker (Novex). Electrophoresis was carried out in a Novex gel apparatus at constant voltage of 100 V for 90 minutes. The gel was stained with Coomassie blue for 2 minutes in a microwave oven and for a further period of 20 minutes under gentle shaking. The gel was destained using 50% acid methanol for 1 hour and 10% acid methanol for 4 hours.

Details of the composition of the electrophoresis solutions are as follows:

TRICINE GEL MANUFACTURER:		NOVEX 4202 Sorrento Valley Boulevard San Diego, CA. 92121	
5	GEL SIZE:	8 x 8 cm	
	GEL MATRIX:	Acrylamide/Bis-Acrylamide	
	GEL THICKNESS:	1.0 mm	
	GEL TYPE:	10 - 20% gradient	
10	SAMPLE BUFFER (2X)	To be diluted 1:1 with equal volume of sample in solution.	
		3.0 M Tris-HCL, pH 8.45	3.0 ml
		Glycerol	2.4 ml
		SDS	0.8 g
		0.1% Coomassie Blue G	1.5 ml
		0.1% Phenol Red	0.5 ml
15		De-ionized water	to 10.0 ml
	RUNNING BUFFER:	Tris Base	121 g
		Tricine	179 g
		SDS	10 g
		De-ionized water	to 1 L
20	SAMPLE LOADING VOLUME: 20 $\mu$ l		
	RUNNING CONDITION:	Constant voltage at 100 V	
	GEL APPARATUS:	NOVEX	
	POWER SUPPLY:	NOVEX	
	STAINING OF GEL:		
25	STAINING SOLUTION:	Coomassie Blue R-250	0.5 g
		Methanol	800 ml
		Acetic acid	140 ml
		De-ionized water	to 2 L
	DESTAINING SOLUTIONS:		
30	SOLUTION I. (50% ACID METHANOL)	Methanol	500 ml
		Acetic acid	100 ml
		De-ionized water	to 1 L
35	SOLUTION II. (10% ACID METHANOL)	Methanol	100 ml
		Acetic acid	70 ml
		De-ionized water to	1 L

A photograph of the electrophoretic gel obtained from the isolate from about 1000 ml of human serum using the foregoing procedure is shown in Figure 6. As can be seen, four major bands lie in the molecular weight range of 4 to 12K in the Tricine SDS electrophoretic gel.

### WESTERN TRANSFER FROM SDS GEL TO PVDF MEMBRANE

A PVDF membrane (Novex) was soaked in 100% methanol for fifteen minutes, rinsed with transfer buffer, and soaked in the buffer for another fifteen minutes before use.

The destained gel was rinsed two times in the transfer buffer and then soaked in the buffer for about fifteen minutes. The cathode of a Novex gel transfer unit was wetted with the buffer and one mesh placed on the cathode. One filter paper was laid on the mesh and the gel onto the filter paper. The pre-soaked PVDF membrane was placed on the gel and another piece of filter paper placed on the membrane. Three layers of mesh were placed on the second filter paper and the anode (pre-wetted in buffer) onto the top mesh. The cathode and anode of the unit were pressed together and installed into the transfer housing and the unit was then filled with transfer buffer. The housing was filled with water and electrodes connected to the power supply. The transfer was carried out at a constant voltage of 30 V for 1½ hours.

After transfer, the membrane was washed with deionized water and dried on a sheet of chromatography paper.

The transfer buffer used in the above steps had the following composition: 12 mM Tris and 96 mM glycine in 20% methanol at pH 8.3.

### ISOLATION OF BANDS FROM PVDF MEMBRANE

Bands labelled 0, 1, 2, 3 and 5 in Figure 6 were cut from the membrane. An additional band having a molecular weight above the molecular weight range of these bands was cut from the membrane for use as a control.

The polypeptides were separately eluted from the bands using the following procedure. A band was soaked in 3 ml of 70% isopropanol and 0.1% TFA overnight at 37°C. The soaking solution was collected and another was added and the band soaked for another two hours at 37°C. The two 3 ml solutions were pooled and evaporated down to about 1 ml in a Speed Vac. The resulting sample was then dialysed against 0.1% acetic acid in a micro-dialyser (Amicon 8MC) to remove dye and SDS. The sample volume was raised to 2 ml with 0.1% acetic acid.

### MODIFIED PROCEDURE FOR FACTIONATION OF HUMAN SERUM PROTEIN AND POLYPEPTIDE FRACTIONS WITH MOLECULAR WEIGHTS BETWEEN 3K AND 30K BY TRICINE SDS GEL ELECTROPHORESIS

A 1000 ml volume of human serum was filtered as described above, and concentrated down to 100 ml.

The pH of the concentrated filtrate was adjusted to about 8.8 with TEAA buffer. 5 g of Millipore Acell™ QMA packing was equilibrated with 25 mM TEAA (pH 8.8). The packing was added to the serum extract and stirred for 15 minutes. The packing was filtered off and the filtrate collected. Another 5 g of the same packing was equilibrated with 25 mM TEAA (pH 9.45) and then added to the filtrate and stirred for 15 minutes. The packing was then transferred to a disposable



minicolumn (15 ml capacity) and washed with a weak ammonia solution (pH 10.2). Polypeptides adsorbed to the packing were eluted with 8 ml of 0.1% acetic acid and the sample lyophilized.

The lyophilized material was dissolved in 200  $\mu$ l of loading buffer and treated as described above. Electrophoresis was carried out on a 25  $\mu$ l volume of sample as described above for two hours.

A photograph of the electrophoretic gel obtained from the isolate from about 1000 ml of human serum using the foregoing procedure is shown in Figure 7. Six bands, labelled A to F in Figure 7, within the molecular weight range of 4 to 10 K were cut out and ground up and soaked in 3 ml of 50 mM  $\text{NH}_4\text{HCO}_3$  and 0.1% SDS for 12 hours at 37°C. The supernatant was collected and another 3 ml of the same buffer was added to the gel and soaked for another 6 hours. The supernatant was pooled and dialysed against 0.1% acetic acid with a MWCO membrane of 1K, using the Amicon 8MC microdialyzer. The final volume of the dialysed sample was adjusted to 4 ml with 0.1% acetic acid.

#### 15 BIOLOGICAL TESTING FOR ACTIVITY OF POLYPEPTIDES ISOLATED ACCORDING TO MODIFIED FRACTIONATION PROCEDURE

The bone apposition rate was measured over a period of 48 hours as described above on six groups of rats using 1 ml of the eluted peptide. Each solution was injected intramuscularly into a group of animals followed by tetracycline at 24 mg per kg of bodyweight. Sections of the lower femoral metaphysis were used for bone apposition measurements. The results are presented in Table One and shown graphically in Figure 8.

**TABLE ONE: Comparison of the Group Arithmetic Means of Bone Apposition Rates ( $\mu\text{m/day}$ ) Among Groups (Bands A, B, C, D, E and F of Figure 7)**

BAND	A	B	C	D	E	F
MEAN	0.85	0.85	0.91	1.23	0.90	0.87
S.D.	0.02	0.06	0.11	0.50	0.11	0.04
N	4	4	4	3	4	4

#### SEQUENCING OF MATERIAL ISOLATED FROM PVDF MEMBRANE

The material of Band 2 shown in Figure 6, which corresponds to Band D of Figure 7 was sequenced according to standard procedures. The sequence of the first eighteen N-terminal amino acids were found to be: Asp Ser Asp Leu Tyr Ala Glu Leu Arg Xaa Met Xaa Ile Lys Thr Thr Ser Gly (SEQ ID NO:5), this sequence approximately corresponding with the first nineteen amino acids given for a variant of NAP-2, described by Walz *et al.* (27), identified herein as SEQ ID NO:4 or NAP-2V.

An analysis of total amino acid content of the polypeptide isolated from human serum also gave good agreement with the amino acid content of NAP-2V. Correspondence of all acid

residues measured (i.e., all residues except asparagine, cysteine and glutamine) was within one or two of the expected content except for leucine, isoleucine and lysine. This is a common observation for leucine and isoleucine, but not for lysine.

#### ACTIVITY OF NAP-2 AND NAP-2V IN RATS

5 Polypeptides having the sequences of NAP-2 (SEQ ID NO:2) and NAP-2V (SEQ ID NO:4) were thus chemically synthesized directly according to standard methods and experiments were conducted to determine whether the chemically synthesized polypeptides displayed activity.

Experiments were conducted simultaneously on three groups of male Sprague-Dawley rats, there being five rats in each group. Each rat weighed between 250 and 350 g. Each rat of the first group was given, by subcutaneous injection into the left gluteus maximus region, 200  $\mu$ l of a 1% aqueous acetic acid solution containing 25 nmol (about 191  $\mu$ g) of NAP-2 (SEQ ID NO:2). Each rat of the second group was similarly given 200  $\mu$ l of a 1% aqueous acetic acid solution containing 25 nmol (about 207  $\mu$ g) of NAP-2V (SEQ ID NO:4). Each rat of the third group, the control group, was similarly given 200  $\mu$ l of 1% acetic acid solution.

15 Immediately following administration of the test solution, 300  $\mu$ l of an aqueous solution of tetracycline hydrochloride was administered intramuscularly into the right gluteus maximus, the concentration of tetracycline being sufficient to obtain a dosage of about 24mg/kg of rat body weight. A second dose of tetracycline hydrochloride solution was administered about 48 hours after the first dose. The rats were sacrificed about 24 hours after administration of the second dose of tetracycline.

Sections of the lower metaphysis of the right femur were used for bone measuring the bone mineral apposition rate. The results obtained are summarized in Table Two and Figure 9.

25

TABLE TWO: Comparison of the Group Arithmetic Means of Bone Apposition Rates ( $\mu$ m/day) Among Groups Administered with NAP-2, NAP-2V and control solutions shown in Figure 9			
	Control	NAP-2	NAP-2V
Mean	0.99 $\mu$ m/d	1.23 $\mu$ m/d	1.28 $\mu$ m/d
S.D.	0.04	0.05	0.08
N	5	5	5
	t	d.f.	p
Control Group vs NAP-2	7.91	8	<0.001
Control Group vs NAP-2V	7.03	8	<0.001
NAP-2 vs NAP-2V	1.15	8	>0.20

30

Polypeptides having the sequence of NAP-2 (SEQ ID NO:2) or of NAP-2V (SEQ ID NO:4) have thus been found to stimulate bone growth.

It has been postulated that NAP-2 contains two internal disulfide bonds, between Cys-5 and Cys-31, and Cys-7 and Cys-47, respectively (28). By extension, NAP-2V would contain  
5 similar linkages between Cys-10 and Cys-36, and Cys-12 and Cys-52 residues, respectively.

It will of course be understood, without the intention of being limited thereby, that a variety of substitutions of amino acids is possible while "preserving" the three-dimensional structure responsible for the bone stimulatory effect of the polypeptides disclosed herein. It is thus expected, for example, that interchange among non-polar aliphatic neutral amino acids, glycine, alanine, proline,  
10 valine and isoleucine, would be possible. Likewise, substitutions among the polar aliphatic neutral amino acids, serine, threonine, methionine, cysteine, asparagine and glutamine could possibly be made. This being said, the intramolecular disulfide bridges might be of importance, and if so the cysteine residues should probably be held intact and other amino acids capable of forming a disulfide linkage not be substituted elsewhere in the sequence. Substitutions among the charged acidic amino acids,  
15 aspartic acid and glutamic acid, could probably be made, as could substitutions among the charged basic amino acids, lysine and arginine. Substitutions among the aromatic amino acids, including phenylalanine, histidine, tryptophan and tyrosine would also likely be possible. These sorts of substitutions and interchanges are well known to those skilled in the art. Other substitutions might well be possible. It is thought that a peptide having an amino acid sequence with about 50% homology or  
20 more with either of the sequences identified as SEQ ID NO:2 or SEQ ID NO:4 may well retain part or all of the bone stimulating activity of the NAP-2/NAP-2V sequence. In the context of this invention, a peptide containing an amino acid sequence that can be aligned with, for example, that of SEQ ID NO:4 such that at least about 50% of individual amino acid residues of the NAP-2V sequence are conserved, allowing for a limited number of insertions or deletions between aligned sequences, would meet this  
25 criterion. Of course, it would also be expected that the greater percentage of homology, say 60%, 70%, 80%, 90%, or more, could increase the degree of retained bone stimulating activity.

Insofar as deletion of one or more amino acids is concerned, it is likely that deletions of a small number of amino acids from each end of the sequence might be possible, this already having been shown for the N-terminus of NAP-2V. Further, symmetrical, or nearly symmetrical deletions  
30 would likely be the most possible to be made while retaining the three-dimensional configuration. Internal deletions, although likely to be possible to some limited extent, should be few, and should probably amount to no more than about five amino acids.

Additions of amino acids could very likely be made at the ends of the sequence, and as with deletions, symmetrical or nearly symmetrical additions to the carboxy and amino terminals are  
35 likely to be possible. Internal additions, although likely to be possible to some limited extent, should be few, and should probably amount to no more than about five amino acids, and preferably fewer.

Of the above-listed modifications to the sequence, terminal additions, deletions or substitutions are most likely to be most useful, as such a modification can serve a variety of functions: an identifying group as for use in a radioimmunoassay; or a linking group, as examples.

Compounds used according to this invention are administered as treatments to promote bone growth, in the treatment of osteoporosis, for example, by any suitable route. The preferred routes are suitable for delivery of polypeptide-type compounds to the bloodstream of a subject, bearing in mind proper storage and handling conditions required for polypeptides such as those described herein.

The daily dosage administered will depend on the subject and to which effect such administration is to give. In the above examples involving NAP-2 and NAP-2V, about 1 mg per kg of bodyweight of rat subject was used per administration. In practice, particularly as human subjects are concerned, the daily dosage may well be between 0.01 and 100 mg or more per kg of bodyweight. More preferably, the dosage would be in the neighbourhood of from about 0.1 to about 10 mg per kg of bodyweight. It may be that the preferred frequency of administration would be greater or less than once per day, depending upon the route of administration, convenience, and the variation of effectiveness of treatment with frequency of and amount used per administration.

The present invention further provides use of any the compounds, such as NAP-2, NAP-2V, etc., in the manufacture or preparation of formulations, and especially pharmaceutical formulations, for use in promoting bone growth, and particularly, treatment of osteoporosis. The invention also provides the pharmaceutical formulations for such use, themselves.

Pharmaceutical preparations include any of the compounds prepared as an injectable solution, including an injectable solution prepared just prior to use, for promoting bone growth and/or treatment of osteoporosis.

Pharmaceutical preparations include the employment of the compounds in admixture with conventional excipients, that is, pharmaceutically acceptable organic or inorganic carrier substances which do not deleteriously react with the compounds, and which possibly enhance the storage and handling stability of the compounds. The preparative procedure may include the sterilization of the pharmaceutical preparations. The compounds may be mixed with auxiliary agents such as lubricants, preservatives, stabilizers, salts for influencing osmotic pressure, etc., which do not react deleteriously with the compounds.

Methods of treatment within the scope of this invention also include the use of physiologically acceptable salts of the compounds defined within the claims, for example, those derived from inorganic acids such as hydrochloric, sulphuric, phosphoric acid, etc.

The dosage of any one or more of the compounds will depend on many factors including the specific compound or combination of compounds being utilized, the mode of administration, and the mammal being treated. Dosages of a particular compound or combination of compounds can be determined using conventional considerations; for example, by customary comparison of the differential activities of the subject compounds and that of a known agent, that is, by means of an appropriate pharmacological protocol in which, for example, bone density of subjects is measured over time.

In one embodiment, the pharmaceutical formulation is administered intravenously once per day in unit doses comprising NAP-2V (or alternatively, NAP-2) in the range of 0.1 to 10 mg per kg of bodyweight.

The polypeptides disclosed herein can be used to obtain antisera thereto (29), this  
5 apparently having been accomplished at least for the polypeptide having the sequence of CTAP-III (SEQ ID NO:3) (28). Methodology and products can be developed using an antibody to a polypeptide for use in detecting the polypeptide with which the antibody binds.

For example, an antibody can be linked to or conjugated with a reporter system which is set up to indicate positively binding of the polypeptide to the antibody. Well known reporter systems  
10 include radioimmuno assays (RIAs) or immunoradiometric assays (IRMAs). Alternatively, an enzyme-linked immunosorbent assay (ELISA) would have in common with RIAs and IRMAs a relatively high degree of sensitivity, but would generally not rely upon the use of radioisotopes. A visually detectable substance may be produced, or at least one detectable in a spectrophotometer. An assay relying upon fluorescence of a substance bound by the enzyme being assayed could be used. It  
15 will be appreciated that there are a number of reporter systems which may be used, according to the present invention, to detect the presence of a particular polypeptide. With standardized sample collection and treatment, polypeptide presence above a threshold amount in blood serum could well be determined.

Such a method based on antigenic response to NAP-2 (SEQ ID NO:2) or NAP-2V  
20 (SEQ ID NO:4) could be developed. Variants of the polypeptide obtained, as described above for amino acid substitution, deletion and addition, (and conjugates) could then be pre-screened as potential bone stimulating factors. Those that react positively with the antibody to the already known peptide could then be tested for bone stimulatory effects *in vivo* using the system described herein for rats, for example.

25 Such an antibody-linked reporter system could be used in a method for determining whether blood serum of a subject contains a deficient amount of the polypeptide. Given a normal threshold concentration of such a polypeptide in blood serum of a given type of subject, test kits could thus be developed.

A further advantage may be obtained through chimeric forms of the protein, as known  
30 in the art. A DNA sequence encoding the entire protein, or a portion of the protein, could thus be linked with a sequence coding for the C-terminal portion of *E. coli*  $\beta$ -galactosidase to produce a fusion protein, for example. An expression system for human respiratory syncytial virus glycoproteins F and G is described in United States Patent No. 5,288,630, issued February 22, 1994, and references cited therein, for example.

## REFERENCES

1. Tam, C.S. 1989. The Pathogenesis of Metabolic Bone Disease: An Overview. In *Metabolic Bone Disease: Cellular and Tissue Mechanisms*. Eds. Tam, C.S., Heersche, J.N.M and Murray, T.M. CRC Press, Boca Raton.
- 5 2. Parfitt A.M., Villanueva, A.R., Mathews, C.H.E., Aswani, S.A. 1980. Kinetics of matrix and mineral apposition in osteoporosis and renal osteodystrophy: relation of rate of turnover to cell morphology, *Metab Bone Dis Rel Res*, 2(S), 213.
3. Parfitt A.M. 1982. The coupling of bone formation to bone resorption: A critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. *Metab Bone Dis Rel Res* 4, 1.
- 10 4. Coccia, P.F., Krivit, W., Cerveuka, J., Clawson, C., Kersey, J., Kim, T.H., Nesbit, M.E., Ramsey, N.K.C., Warkentin, P.I., Teitelbaum, S.L., Kahn, A.J., Brown, D.M. 1980. Successful bone marrow transplantation for infantile malignant osteopetrosis. *New Eng J. Med*, 320, 701.
- 15 5. Marks, S.C. Jr., Walker, D.G. 1981. The hematogenous origin of osteoclast: evidence from osteopetrotic (microphthalmic) mice treated with spleen cell from geige mouse donor. *Am J Anat* 161,1.
6. Owen M. 1985. Lineage of osteogenic cells and their relationship to the stromal system. In *Bone and Mineral Research*, Vol 3, Ed. Peck W.A. Amsterdam 1.
- 20 7. Yamamoto, I. 1985. Regulation of receptors for parathyroid hormone in rat osteosarcoma cells. *J.J.B.M.* 3,38.
8. Canalis, E. 1986. Interleukin-1 has independent effects on deoxyribonucleic acid and collagen synthesis in cultures of rat calvariae, *Endocrinol* 118, 74.
9. Centrella, M., Canalis, E. 1985. Transforming and non-transforming growth factor are present in medium conditioned by fetal rat calvariae. *Proc Natl Acad Sci, U.S.A.* 82, 7355.
- 25 10. Canalis, E. 1985. Effect of growth factors on bone cell replication and differentiation. *Clin Orthop* 183, 246.
11. Chyun, Y.S., Raisz, L.G. 1984. Stimulation of bone formation by prostaglandin E2. *Prostaglandins*, 27, 97.
- 30 12. Canalis, E. 1980. Effects of insulin-like growth factor 1 on DNA and protein synthesis in cultured rat calvariae. *J Clin Invest*, 66, 709.
13. Klein, D.C., Raisz, L.G. 1970. Prostaglandins: stimulation of bone resorption in tissue culture. *Endocrinol* 86 1436.
- 35 14. Tashjian A.H., Jr., Voekel, E.F., Lazarro, M., Singer, F.R., Roberts, A., Derynck, R., Winkler, M.E., Levine, L. 1985. a and b human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvariae. *Proc Natl Acad Sci, U.S.A.* 82, 4535.

15. Chen, T.L., Cone, C.M., Morey-Holton, E., Feldman, D. 1982. Glucocorticoid regulation of 1,25(OH)<sub>2</sub>D<sub>3</sub> receptors on cultured mouse bone cells. *J. Biol Chem* 257, 13563.
16. Roodman, G.D. 1992. Perspectives: Interleukin-6: An osteotropic factor. *J. Bone Miner Res*, 7, 475.
- 5 17. Segre G.V. 1990 Secretion, metabolism and circulating heterogeneity of parathyroid hormone. In *Primer in Metabolic Bone diseases and Disorders of Mineral Metabolism*. First Edition. ed. Favus, M.J., Kelseyville, California.
18. Seiy H. 1933. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. *Endocrinol* 16, 547.
- 10 19. Aitken R.E., Kerr J.L., Loyd H.M. 1964. Primary hyperparathyroidism with osteosclerosis and calcification in articular cartilage. *Am J Med* 37, 813.
20. Connor T.B., Freijances J., Stoner R.E., Martin L.G., Jowsey J. 1973. Generalized osteosclerosis in primary hyperparathyroidism. *Trans Am Clin Climatol Assoc* 85, 185.
21. Gennant H.K., Baron J.M., Paloyan E., Jowsey J. 1975. Osteosclerosis in primary hyperparathyroidism. *Am J Med* 59, 104.
- 15 22. Kalu, D.N., Pennock J., Doyle, F.H., Foster G.V. 1970. Parathyroid hormone and experimental osteosclerosis. *Lancet* 1, 1363.
23. Tam C.S., Harrison J.E., Reed R., Cruickshank B. 1978. Bone apposition rate as an index of bone metabolism. *Metabolism* 27, 143.
- 20 24. Tam C.S., Bayley T.A., Harrison J.E., Murray T.M., Birkin B.L., Thompson D. 1978. Bone biopsy in the diagnosis of primary hyperparathyroidism. In *Copp D.H., Talmage R.V. (eds) Endocrinology of Calcium Metabolism*. Excerpta Medica, Amsterdam, p 427 (Abstract).
- 25 25. Tam, C.S., Heersche, J.N.M., Murray, T.M., Parsons J.A. 1982. Parathyroid hormone stimulates the apposition rate independent of its resorptive action: Differential effects of intermittent and continuous administration. *Endocrinol* 110, 506.
26. Majundar, S., Gonder, D., Koutsis, B., Poncz, M. 1991. Characterization of Human  $\beta$ -Thromboglobulin Gene. *J. Biol Chem* 266, 578
27. Walz, A., Baggiolini, M. 1990. Generation of the Neutrophil-Activating Peptide NAP-2 from Platelet Basic Protein or Connective Tissue-Activating Peptide III Through Monocyte Proteases. *J. Exp Med* 171, 449.
- 30 28. Baggiolini, M., Clemetson, K.J., Walz, A. International Patent Application No. PCT/EP89/01389, published June 14, 1990 under WO90/06321.
29. Basic & Clinical Immunology, (7th Edition) eds. Stites, Daniel P., Terr, Abba I, Appleton and Lange, Norwalk, Connecticut, San Matea, California, 1991.

## Sequence Listing

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

(A) NAME: OSTEOPHARM LIMITED  
 (B) STREET: 100 International Boulevard  
 (C) CITY: Etobicoke  
 (D) PROVINCE: Ontario  
 (E) COUNTRY: CA  
 (F) POSTAL CODE (ZIP) : M9W 6J6

(A) NAME: TAM, Cherk Shing  
 (B) STREET: 1072 Rectory Lane  
 (C) CITY: Oakville  
 (D) PROVINCE: Ontario  
 (E) COUNTRY: CA  
 (F) POSTAL CODE (ZIP) : L6M 2B7

(ii) TITLE OF INVENTION: BONE STIMULATING FACTOR

(iii) NUMBER OF SEQUENCES: 5

## (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage  
 (B) COMPUTER: COMPAQ, IBM PC compatible  
 (C) OPERATING SYSTEM: MS-DOS 5.1  
 (D) SOFTWARE: WORD PERFECT

## (v) CURRENT APPLICATION DATA:

APPLICATION NUMBER:

## (vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/229,009  
 (B) FILING DATE: 18-APR-1994

## (2) INFORMATION FOR SEQ ID NO:1

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 81 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1

Gly Lys Glu Glu Ser Leu Asp Ser Asp Leu Tyr Ala Glu Leu Arg Cys  
 1 5 10 15  
 Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro Lys Asn Ile Gln Ser  
 20 25 30  
 Leu Glu Val Ile Gly Lys Gly Thr His Cys Asn Gln Val Glu Val Ile  
 35 40 45  
 Ala Thr Leu Lys Asp Gly Arg Lys Ile Cys Leu Asp Pro Asp Ala Pro  
 50 55 60  
 Arg Ile Lys Lys Ile Val Gln Lys Lys Leu Ala Gly Asp Glu Ser Ala  
 65 70 75 80  
 Asp



21

## (2) INFORMATION FOR SEQ ID NO:2

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 70 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2

Ala Glu Leu Arg Cys Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro  
 1 5 10 15  
 Lys Asn Ile Gln Ser Leu Glu Val Ile Gly Lys Gly Thr His Cys Asn  
 20 25 30  
 Gln Val Glu Val Ile Ala Thr Leu Lys Asp Gly Arg Lys Ile Cys Leu  
 35 40 45  
 Asp Pro Asp Ala Pro Arg Ile Lys Lys Ile Val Gln Lys Lys Leu Ala  
 50 55 60  
 Gly Asp Glu Ser Ala Asp  
 65 70

## (2) INFORMATION FOR SEQ ID NO:3

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 85 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3

Asn Leu Ala Lys Gly Lys Glu Glu Ser Leu Asp Ser Asp Leu Tyr Ala  
 1 5 10 15  
 Glu Leu Arg Cys Met Cys Ile Lys Thr Thr Ser Gly Ile His Pro Lys  
 20 25 30  
 Asn Ile Gln Ser Leu Glu Val Ile Gly Lys Gly Thr His Cys Asn Gln  
 35 40 45  
 Val Glu Val Ile Ala Thr Leu Lys Asp Gly Arg Lys Ile Cys Leu Asp  
 50 55 60  
 Pro Asp Ala Pro Arg Ile Lys Lys Ile Val Gln Lys Lys Leu Ala Gly  
 65 70 75 80  
 Asp Glu Ser Ala Asp  
 85

## (2) INFORMATION FOR SEQ ID NO:4

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 75 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4

Asp Ser Asp Leu Tyr Ala Glu Leu Arg Cys Met Cys Ile Lys Thr Thr  
 1 5 10 15  
 Ser Gly Ile His Pro Lys Asn Ile Gln Ser Leu Glu Val Ile Gly Lys  
 20 25 30  
 Gly Thr His Cys Asn Gln Val Glu Val Ile Ala Thr Leu Lys Asp Gly  
 35 40 45  
 Arg Lys Ile Cys Leu Asp Pro Asp Ala Pro Arg Ile Lys Lys Ile Val  
 50 55 60  
 Gln Lys Lys Leu Ala Gly Asp Glu Ser Ala Asp  
 65 70 75

## (2) INFORMATION FOR SEQ ID NO:5

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5

Asp Ser Asp Leu Tyr Ala Glu Leu Arg Xaa Met Xaa Ile Lys Thr Thr  
 1 5 10 15  
 Ser Gly

## CLAIMS

1. A method of increasing bone growth in a mammal by administering a therapeutically effective amount of a polypeptide having the amino acid sequence Asp-Ser-Asp-Leu-Tyr-Ala-Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-Ser-Leu-Glu-Val-Ile-Gly-Lys-Gly-Thr-His-Cys-Asn-Gln-Val-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asp-Gly-Arg-Lys-Ile-Cys-Leu-Asp-Pro-Asp-Ala-Pro-Arg-Ile-Lys-Lys-Ile-Val-Gln-Lys-Lys-Leu-Ala-Gly-Asp-Glu-Ser-Ala-Asp or the amino acid sequence Ala-Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-Ser-Leu-Glu-Val-Ile-Gly-Lys-Gly-Thr-His-Cys-Asn-Gln-Val-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asp-Gly-Arg-Lys-Ile-Cys-Leu-Asp-Pro-Asp-Ala-Pro-Arg-Ile-Lys-Lys-Ile-Val-Gln-Lys-Lys-Leu-Ala-Gly-Asp-Glu-Ser-Ala-Asp.
2. A method of increasing bone growth in a mammal by administering a therapeutically effective amount of a polypeptide having the amino acid sequence Asp-Ser-Asp-Leu-Tyr-Ala-Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-Ser-Leu-Glu-Val-Ile-Gly-Lys-Gly-Thr-His-Cys-Asn-Gln-Val-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asp-Gly-Arg-Lys-Ile-Cys-Leu-Asp-Pro-Asp-Ala-Pro-Arg-Ile-Lys-Lys-Ile-Val-Gln-Lys-Lys-Leu-Ala-Gly-Asp-Glu-Ser-Ala-Asp, Ala-Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-Ser-Leu-Glu-Val-Ile-Gly-Lys-Gly-Thr-His-Cys-Asn-Gln-Val-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asp-Gly-Arg-Lys-Ile-Cys-Leu-Asp-Pro-Asp-Ala-Pro-Arg-Ile-Lys-Lys-Ile-Val-Gln-Lys-Lys-Leu-Ala-Gly-Asp-Glu-Ser-Ala-Asp, a portion of one of said sequences capable of increasing bone growth, or a combination thereof.
3. A method of increasing bone growth in a mammal by administering a therapeutically effective amount of a polypeptide having the amino acid sequence as depicted by SEQ ID NO:2, SEQ ID NO:4, or having an amino acid sequence sufficiently duplicative thereof to be capable of increasing bone growth in the mammal; or a combination of said polypeptides.
4. A method of increasing bone growth in a mammal by administering a therapeutically effective amount of a polypeptide having an amino acid sequence having at least about 50% homology with SEQ ID NO: 2, SEQ ID NO:4, or a combination thereof.
5. The method of increasing bone growth in a mammal according to claim 4 wherein the amino acid sequence has at least about 60% homology with SEQ ID NO: 2 or SEQ ID NO:4.
6. The method of increasing bone growth in a mammal according to claim 5 wherein the amino acid sequence has at least about 70% homology with SEQ ID NO:2 or SEQ ID NO:4.
7. The method of increasing bone growth in a mammal according to claim 6 wherein the amino acid sequence has at least about 80% homology with SEQ ID NO:4.

8. The method of increasing bone growth in a mammal according to claim 7 wherein the amino acid sequence has at least about 90% homology with SEQ ID NO:2 or SEQ ID NO:4.
- 5 9. A method of increasing bone growth in a mammal by administering a therapeutically effective amount of a polypeptide having the amino acid sequence Asp-Ser-Asp-Leu-Tyr-Ala-Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-Ser-Leu-Glu-Val-Ile-Gly-Lys-Gly-Thr-His-Cys-Asn-Gln-Val-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asp-Gly-Arg-Lys-Ile-Cys-Leu-Asp-Pro-Asp-Ala-Pro-Arg-Ile-Lys-Lys-Ile-Val-Gln-Lys-Lys-Leu-Ala-Gly-Asp-Glu-Ser-Ala-Asp, analogues thereof wherein the amino acids in the sequence may be substituted, deleted or added, so long as the bone stimulatory activity in mammals derived from the three dimensional conformation of the sequence is preserved, conjugates of the polypeptide or analogues thereof; the amino acid sequence Ala-Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys-Thr-Thr-Ser-Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-Ser-Leu-Glu-Val-Ile-Gly-Lys-Gly-Thr-His-Cys-Asn-Gln-Val-Glu-Val-Ile-Ala-Thr-Leu-Lys-Asp-Gly-Arg-Lys-Ile-Cys-Leu-Asp-Pro-Asp-Ala-Pro-Arg-Ile-Lys-Lys-Ile-Val-Gln-Lys-Lys-Leu-Ala-Gly-Asp-Glu-Ser-Ala-Asp, analogues thereof, conjugates of the polypeptide or analogues thereof; or a combination thereof.
- 10 10. A method for determining the presence of a polypeptide that increases bone growth in a mammal in a fluid sample of a mammal, comprising linking an antibody to a polypeptide of claim 1 to a reporter system and exposing the linked antibody to the sample such that the reporter system produces a detectable response when a predetermined amount of the polypeptide and the antibody are bound together.
- 20 11. A method for determining the presence of a polypeptide that increases bone growth in a mammal in a fluid sample of a mammal, comprising linking an antibody to a polypeptide of claim 2 to a reporter system and exposing the linked antibody to the sample such that the reporter system produces a detectable response when a predetermined amount of the polypeptide and the antibody are bound together.
- 25 12. A method for determining the presence of a polypeptide that increases bone growth in a mammal in a fluid sample of a mammal, comprising linking an antibody to a polypeptide of claim 3 to a reporter system and exposing the linked antibody to the sample such that the reporter system produces a detectable response when a predetermined amount of the polypeptide and the antibody are bound together.
- 30 13. A method for determining the presence of a polypeptide that increases bone growth in a mammal in a fluid sample of a mammal, comprising linking an antibody to a polypeptide of claim 4 to a reporter system and exposing the linked antibody to the sample such that the reporter system produces a detectable response when a predetermined amount of the polypeptide and the antibody are bound together.
- 35

14. A method for determining the presence of a polypeptide that increases bone growth in a mammal in a fluid sample of a mammal, comprising linking an antibody to a polypeptide of claim 5 to a reporter system and exposing the linked antibody to the sample such that the reporter system produces a detectable response when a predetermined amount of the polypeptide and the antibody are bound together.
15. A method for determining the presence of a polypeptide that increases bone growth in a mammal in a fluid sample of a mammal, comprising linking an antibody to a polypeptide of claim 6 to a reporter system and exposing the linked antibody to the sample such that the reporter system produces a detectable response when a predetermined amount of the polypeptide and the antibody are bound together.
16. A method for determining the presence of a polypeptide that increases bone growth in a mammal in a fluid sample of a mammal, comprising linking an antibody to a polypeptide of claim 7 to a reporter system and exposing the linked antibody to the sample such that the reporter system produces a detectable response when a predetermined amount of the polypeptide and the antibody are bound together.
17. A method for determining the presence of a polypeptide that increases bone growth in a mammal in a fluid sample of a mammal, comprising linking an antibody to a polypeptide of claim 8 to a reporter system and exposing the linked antibody to the sample such that the reporter system produces a detectable response when a predetermined amount of the polypeptide and the antibody are bound together.
18. A method for determining the presence of a polypeptide that increases bone growth in a mammal in a fluid sample of a mammal, comprising linking an antibody to a polypeptide of claim 9 to a reporter system and exposing the linked antibody to the sample such that the reporter system produces a detectable response when a predetermined amount of the polypeptide and the antibody are bound together.
19. A method of detecting the presence of a protein exhibiting bone stimulatory activity in mammals, the method comprising the steps of:  
collecting a blood serum sample from the mammal; and  
exposing at least a portion of the sample to an antibody linked to a reporter system,  
wherein the antibody is capable of binding to a polypeptide having the sequence of a polypeptide of claim 1 and wherein binding of the protein and antibody together causes the reporter system to indicate said binding.
20. A method of detecting the presence of a protein exhibiting bone stimulatory activity in mammals, the method comprising the steps of:  
collecting a blood serum sample from the mammal; and  
exposing at least a portion of the sample to an antibody linked to a reporter system,  
wherein the antibody is capable of binding to a polypeptide having the sequence of a polypeptide of claim 2 and wherein binding of the protein and antibody together causes the reporter system to indicate said binding.

21. A method of detecting the presence of a protein exhibiting bone stimulatory activity in mammals, the method comprising the steps of:  
collecting a blood serum sample from the mammal; and  
exposing at least a portion of the sample to an antibody linked to a reporter system,  
5 wherein the antibody is capable of binding to a polypeptide having the sequence of a polypeptide of claim 3 and wherein binding of the protein and antibody together causes the reporter system to indicate said binding.
22. A method of detecting the presence of a protein exhibiting bone stimulatory activity in mammals, the method comprising the steps of:  
10 collecting a blood serum sample from the mammal; and  
exposing at least a portion of the sample to an antibody linked to a reporter system,  
wherein the antibody is capable of binding to a polypeptide having the sequence of a polypeptide of claim 4 and wherein binding of the protein and antibody together causes the reporter system to indicate said binding.
23. A method of detecting the presence of a protein exhibiting bone stimulatory activity in mammals, the method comprising the steps of:  
15 collecting a blood serum sample from the mammal; and  
exposing at least a portion of the sample to an antibody linked to a reporter system,  
wherein the antibody is capable of binding to a polypeptide having the sequence of a polypeptide of claim 5 and wherein binding of the protein and antibody together causes the reporter system to indicate said binding.
24. A method of detecting the presence of a protein exhibiting bone stimulatory activity in mammals, the method comprising the steps of:  
20 collecting a blood serum sample from the mammal; and  
exposing at least a portion of the sample to an antibody linked to a reporter system,  
wherein the antibody is capable of binding to a polypeptide having the sequence of a polypeptide of claim 6 and wherein binding of the protein and antibody together causes the reporter system to indicate said binding.
25. A method of detecting the presence of a protein exhibiting bone stimulatory activity in mammals, the method comprising the steps of:  
25 collecting a blood serum sample from the mammal; and  
exposing at least a portion of the sample to an antibody linked to a reporter system,  
wherein the antibody is capable of binding to a polypeptide having the sequence of a polypeptide of claim 7 and wherein binding of the protein and antibody together causes the reporter system to indicate said binding.
- 30  
35

26. A method of detecting the presence of a protein exhibiting bone stimulatory activity in mammals, the method comprising the steps of:  
collecting a blood serum sample from the mammal; and  
exposing at least a portion of the sample to an antibody linked to a reporter system,  
5 wherein the antibody is capable of binding to a polypeptide having the sequence of a polypeptide of claim 8 and wherein binding of the protein and antibody together causes the reporter system to indicate said binding.
27. A method of detecting the presence of a protein exhibiting bone stimulatory activity in mammals, the method comprising the steps of:  
10 collecting a blood serum sample from the mammal; and  
exposing at least a portion of the sample to an antibody linked to a reporter system,  
wherein the antibody is capable of binding to a polypeptide having the sequence of a polypeptide of claim 9 and wherein binding of the protein and antibody together causes the reporter system to indicate said binding.
- 15 28. A method of diagnosing a diseased condition such as osteoporosis in a mammal, the method comprising the steps of:  
collecting a blood serum sample from the mammal;  
ascertaining whether the amount of a polypeptide having the sequence of a polypeptide of claim 1 exceeds a predetermined level; and  
20 wherein a said amount of the polypeptide below the pre-determined level indicates said diseased condition.
29. A method of diagnosing a diseased condition such as osteoporosis in a mammal, the method comprising the steps of:  
collecting a blood serum sample from the mammal;  
25 ascertaining whether the amount of a polypeptide having the sequence of a polypeptide of claim 2 exceeds a predetermined level; and  
wherein a said amount of the polypeptide below the pre-determined level indicates said diseased condition.
30. A method of diagnosing a diseased condition such as osteoporosis in a mammal, the method comprising the steps of:  
30 collecting a blood serum sample from the mammal;  
ascertaining whether the amount of a polypeptide having the sequence of a polypeptide of claim 3 exceeds a predetermined level; and  
wherein a said amount of the polypeptide below the pre-determined level indicates said  
35 diseased condition.

31. A method of diagnosing a diseased condition such as osteoporosis in a mammal, the method comprising the steps of:  
collecting a blood serum sample from the mammal;  
ascertaining whether the amount of a polypeptide having the sequence of a polypeptide of  
5 claim 4 exceeds a predetermined level; and  
wherein a said amount of the polypeptide below the pre-determined level indicates said diseased condition.
32. A method of diagnosing a diseased condition such as osteoporosis in a mammal, the method comprising the steps of:  
10 collecting a blood serum sample from the mammal;  
ascertaining whether the amount of a polypeptide having the sequence of a polypeptide of claim 5 exceeds a predetermined level; and  
wherein a said amount of the polypeptide below the pre-determined level indicates said diseased condition.
33. A method of diagnosing a diseased condition such as osteoporosis in a mammal, the method comprising the steps of:  
15 collecting a blood serum sample from the mammal;  
ascertaining whether the amount of a polypeptide having the sequence of a polypeptide of claim 6 exceeds a predetermined level; and  
20 wherein a said amount of the polypeptide below the pre-determined level indicates said diseased condition.
34. A method of diagnosing a diseased condition such as osteoporosis in a mammal, the method comprising the steps of:  
25 collecting a blood serum sample from the mammal;  
ascertaining whether the amount of a polypeptide having the sequence of a polypeptide of claim 7 exceeds a predetermined level; and  
wherein a said amount of the polypeptide below the pre-determined level indicates said diseased condition.
35. A method of diagnosing a diseased condition such as osteoporosis in a mammal, the method comprising the steps of:  
30 collecting a blood serum sample from the mammal;  
ascertaining whether the amount of a polypeptide having the sequence of a polypeptide of claim 8 exceeds a predetermined level; and  
35 wherein a said amount of the polypeptide below the pre-determined level indicates said diseased condition.



36. A method of diagnosing a diseased condition such as osteoporosis in a mammal, the method comprising the steps of:  
collecting a blood serum sample from the mammal;  
ascertaining whether the amount of a polypeptide having the sequence of a polypeptide of  
5 claim 9 exceeds a predetermined level; and  
wherein a said amount of the polypeptide below the pre-determined level indicates said diseased condition.
37. The method of any of claims 28 to 35 wherein a reporter system is linked to an antibody of said polypeptide and the ascertaining step includes exposing at least a portion of the  
10 sample to the antibody, wherein binding of the polypeptide and antibody together causes the reporter system to indicate said binding.
38. The method of any of claims 28 to 35, further comprising the step of isolating a protein fraction of the sample and removing proteins having molecular weights greater than about 30,000 daltons prior to ascertaining the amount of the polypeptide.
- 15 39. A chimeric bone stimulating factor comprising a polypeptide having the amino acid sequence set forth in SEQ ID NO:2, or a portion thereof.
40. A chimeric bone stimulating factor comprising a polypeptide having the amino acid sequence set forth in SEQ ID NO:4, or a portion thereof.
41. A chimeric bone stimulating factor comprising a polypeptide of claim 1; or a portion thereof.  
20
42. A chimeric bone stimulating factor comprising a polypeptide of claim 2; or a portion thereof.
43. A chimeric bone stimulating factor comprising a polypeptide of claim 3; or a portion thereof.
- 25 44. A chimeric bone stimulating factor comprising a polypeptide of claim 4; or a portion thereof.
45. A chimeric bone stimulating factor comprising a polypeptide of claim 5; or a portion thereof.
46. A chimeric bone stimulating factor comprising a polypeptide of claim 6; or a portion thereof.  
30
47. A chimeric bone stimulating factor comprising a polypeptide of claim 7; or a portion thereof.
48. A chimeric bone stimulating factor comprising a polypeptide of claim 8; or a portion thereof.
- 35 49. A chimeric bone stimulating factor comprising a polypeptide of claim 9; or a portion thereof.
50. The use of a polypeptide of claim 1 for the treatment of osteoporosis.
51. The use of a polypeptide of claim 2 for the treatment of osteoporosis.
52. The use of a polypeptide of claim 3 for the treatment of osteoporosis.

53. The use of a polypeptide of claim 4 for the treatment of osteoporosis.
54. The use of a polypeptide of claim 5 for the treatment of osteoporosis.
55. The use of a polypeptide of claim 6 for the treatment of osteoporosis.
56. The use of a polypeptide of claim 7 for the treatment of osteoporosis.
- 5 57. The use of a polypeptide of claim 8 for the treatment of osteoporosis.
58. The use of a polypeptide of claim 9 for the treatment of osteoporosis.
59. The use of a polypeptide of claim 1 to promote bone growth in a mammal.
60. The use of a polypeptide of claim 2 to promote bone growth in a mammal.
61. The use of a polypeptide of claim 3 to promote bone growth in a mammal.
- 10 62. The use of a polypeptide of claim 4 to promote bone growth in a mammal.
63. The use of a polypeptide of claim 5 to promote bone growth in a mammal.
64. The use of a polypeptide of claim 6 to promote bone growth in a mammal.
65. The use of a polypeptide of claim 7 to promote bone growth in a mammal.
66. The use of a polypeptide of claim 8 to promote bone growth in a mammal.
- 15 67. The use of a polypeptide of claim 9 to promote bone growth in a mammal.
68. A pharmaceutical composition for promoting bone growth, comprising a therapeutically effective amount of a polypeptide of claim 1.
69. A pharmaceutical composition for promoting bone growth, comprising a therapeutically effective amount of a polypeptide of claim 2.
- 20 70. A pharmaceutical composition for promoting bone growth, comprising a therapeutically effective amount of a polypeptide of claim 3.
71. A pharmaceutical composition for promoting bone growth, comprising a therapeutically effective amount of a polypeptide of claim 4.
72. A pharmaceutical composition for promoting bone growth, comprising a therapeutically effective amount of a polypeptide of claim 5.
- 25 73. A pharmaceutical composition for promoting bone growth, comprising a therapeutically effective amount of a polypeptide of claim 6.
74. A pharmaceutical composition for promoting bone growth, comprising a therapeutically effective amount of a polypeptide of claim 7.
- 30 75. A pharmaceutical composition for promoting bone growth, comprising a therapeutically effective amount of a polypeptide of claim 8.
76. A pharmaceutical composition for promoting bone growth, comprising a therapeutically effective amount of a polypeptide of claim 9.
77. The use of a polypeptide having a sequence according to claim 1 in the preparation of a medicament for use in promoting bone growth or the treatment of osteoporosis.
- 35 78. The use of a polypeptide having a sequence according to claim 2 in the preparation of a medicament for use in promoting bone growth or the treatment of osteoporosis.
79. The use of a polypeptide having a sequence according to claim 3 in the preparation of a medicament for use in promoting bone growth or the treatment of osteoporosis.

80. The use of a polypeptide having a sequence according to claim 4 in the preparation of a medicament for use in promoting bone growth or the treatment of osteoporosis.
81. The use of a polypeptide having a sequence according to claim 5 in the preparation of a medicament for use in promoting bone growth or the treatment of osteoporosis.
- 5 82. The use of a polypeptide having a sequence according to claim 6 in the preparation of a medicament for use in promoting bone growth or the treatment of osteoporosis.
83. The use of a polypeptide having a sequence according to claim 7 in the preparation of a medicament for use in promoting bone growth or the treatment of osteoporosis.
84. The use of a polypeptide having a sequence according to claim 8 in the preparation of a medicament for use in promoting bone growth or the treatment of osteoporosis.
- 10 85. The use of a polypeptide having a sequence according to claim 9 in the preparation of a medicament for use in promoting bone growth or the treatment of osteoporosis.

1/7




FIG. 1

2/7




FIG. 2




FIG. 3

3/7




FIG. 4




FIG. 5

4/7




FIG. 6

SUBSTITUTE SHEET

5/7




FIG. 7

SUBSTITUTE SHEET